Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: rogermci® who wrote (109)	2/4/2000 1:33:00 AM
From: Edscharp	Respond to of 286

<<Rathmann didn't do beans for ICOS.>> On the one hand, I always felt that ICOS was somewhat over-priced compared to other biotechs and that the premium was clearly due to they hype and presence of Rathman, and of course, Gates. But, everyone who talks about ICOS has told me that ICOS's management and science are first rate. Of course, that and a $1.50 will get you a cup of coffee at Starbucks. Their lead drug candidate, Leukarrest, failed P3 trials last fall. This can happen to any biotech and shouldn't be blamed on any single individual. I do tend to agree that a 100% run-up is a bit much for Rathman's presence. Now, if he could only get Bill Gates to buy 20% of HYSQ then he would have really earned his salary. Regards, Ed [Disclosure: I bought in at $4.50/share and then some more at about $6.50. I'm one happy camper right now.]

To: rogermci® who wrote (109)	2/4/2000 11:14:00 AM
From: Richaaard	Respond to of 286

Did you read my post? Yes Roger read your post but it didn't matter to me. If you want to look at what Roger did for Icos, then you should also look at what he did for Amgen. You post smacks of someone who missed the boat and sold prematurely. BTW, I was a shareholder 3 months ago.